Kimberly-Clark Announces Third Quarter 2014 Results
Executive Summary
- Third quarter 2014 net sales of
$5.4 billion increased 3 percent compared to the year-ago period. Organic sales rose 4 percent, including a 10 percent increase inK-C International . Organic sales exclude the impact of changes in foreign currency exchange rates and lower sales as a result of European strategic changes. - Diluted net income per share for the third quarter was
$1.50 in 2014 and$1.42 in 2013. - Third quarter adjusted earnings per share were an all-time record
$1.61 in 2014 compared to$1.44 in the year-ago period. Performance benefited from organic sales growth, cost savings and a lower share count, while comparisons were negatively impacted by input cost inflation, unfavorable foreign currency exchange rate effects, a higher adjusted effective tax rate and lower net income from equity companies. Adjusted earnings per share in both years exclude certain items described later in this press release. - Full-year adjusted earnings per share in 2014 are expected to be
$5.93 to$6.03 , assuming the spin-off of the company's health care business occurs at the end ofOctober 2014 . This guidance includes a10 cent per share impact from the spin-off of the last two months of 2014 health care earnings. The previous target for adjusted earnings per share was$6.00 to$6.15 and assumed a full year of results for the health care business. - The company is also initiating a restructuring program to improve organization efficiency and offset the impact of stranded overhead costs resulting from the health care spin-off. The restructuring is expected to cost
$130 to$160 million after-tax and generate cumulative pre-tax savings of$120 to$140 million .
Chairman and Chief Executive Officer
Falk added, "The restructuring program we are undertaking will make our organization more efficient, allow us to offset the impact of stranded overhead costs from the spin-off and give us additional flexibility to invest for future growth. This effort is further evidence of how we manage our company with financial discipline and our commitment to generate attractive returns to shareholders."
Third Quarter 2014 Operating Results
Sales of
Operating profit was
The year-over-year adjusted operating profit comparison benefited from organic sales growth and
The third quarter effective tax rate was 34.5 percent in 2014 compared to 30.3 percent in 2013. The third quarter adjusted effective tax rate, which excludes the effects of the previously mentioned items excluded from adjusted earnings per share, was 32.5 percent in 2014 and 30.2 percent in 2013. The company continues to expect a full-year 2014 adjusted effective tax rate between 31.0 and 32.5 percent.
Cash Flow and Balance Sheet
Cash provided by operations in the third quarter of 2014 was
Third quarter 2014 share repurchases were 1.8 million shares at a cost of
Third Quarter 2014 Business Segment Results
Personal Care Segment
Third quarter sales of
Sales in
Sales in
Sales in
Consumer Tissue Segment
Third quarter sales of
Sales in
Sales in
Sales in
K-C Professional (KCP) Segment
Third quarter sales of
Sales in
Sales in
Sales in
Health Care Segment
Third quarter sales of
Year-To-Date Results
For the first nine months of 2014, sales of
Year-to-date operating profit was
Through nine months, diluted net income per share was
Adjusted operating profit and adjusted earnings per share in 2014 exclude transaction and related costs for the company's spin-off of its health care business, a charge related to a regulatory dispute in the
Health Care Business Spin-Off (
In
2014 Organization Restructuring
The company is initiating a restructuring program in order to improve organization efficiency and offset the impact of stranded overhead costs resulting from the spin-off of the company's health care business. The restructuring is intended to improve
The restructuring is expected to be completed by the end of 2016, with total costs anticipated to be
The company expects that
Western and Central European Businesses Strategic Changes - Update
In
2014 Outlook - Update
Adjusted earnings per share in 2014 are expected to be
After the spin-off, historical results for health care will be reported as earnings from discontinued operations. The company's outlook for 2014 adjusted earnings per share of
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:
- Adjusted earnings and earnings per share (including continuing and discontinued operations)
- Adjusted gross and operating profit
- Adjusted other (income) and expense, net
- Adjusted effective tax rate
These non-GAAP financial measures exclude the following items for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:
- Transaction and related costs for the company's spin-off of its health care business. In
November 2013 , the company announced that it was pursuing a tax-free spin-off of its health care business. As a result, the company is incurring incremental costs to evaluate, plan and execute the transaction. - Charge related to regulatory dispute in the
Middle East . In the first quarter of 2014, the company recorded a non-deductible charge as a result of an adverse court ruling regarding the treatment of capital contributions in prior years to a majority-owned affiliate in theMiddle East . - Western and
Central Europe strategic changes and related restructuring charges. (See previous discussion in this news release.) - Balance sheet remeasurement charge due to devaluation of Venezuelan bolivar. In the first quarter of 2013, the company recorded a charge for the remeasurement of the local currency-denominated balance sheet due to the
February 2013 devaluation of the Venezuelan bolivar. - 2014 organization restructuring. (See previous discussion in this news release).
In addition, this press release includes information regarding organic sales, which exclude the impact of changes in foreign currency rates and lower sales in conjunction with European strategic changes and pulp and tissue restructuring actions.
The company provides these non-GAAP financial measures as supplemental information to our GAAP financial measures. Management and the company's Board of Directors use adjusted earnings, adjusted earnings per share and adjusted gross and operating profit to (a) evaluate the company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the company's business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of our ongoing business operations.
Additionally, the
Conference Call
A conference call to discuss this news release and other matters of interest to investors and analysts will be held at
About
Copies of
Certain matters contained in this news release concerning the outlook, anticipated financial and operating results, raw material, energy and other input costs, anticipated currency rates and exchange risks, net income from equity companies, sources and uses of cash, the effective tax rate, the anticipated costs, scope, timing and financial and other effects of the potential spin-off of the health care business, the 2014 organization restructuring and the Western and
|
| ||||||||||
|
CONSOLIDATED INCOME STATEMENT | ||||||||||
|
(Millions, except per share amounts) | ||||||||||
|
Three Months Ended |
||||||||||
|
2014 |
2013 |
Change | ||||||||
|
Net Sales |
$ |
5,442 |
$ |
5,262 |
+3.4 |
% | ||||
|
Cost of products sold |
3,541 |
3,457 |
+2.4 |
% | ||||||
|
Gross Profit |
1,901 |
1,805 |
+5.3 |
% | ||||||
|
Marketing, research and general expenses |
1,011 |
990 |
+2.1 |
% | ||||||
|
Other (income) and expense, net |
(17) |
8 |
N.M. | |||||||
|
Operating Profit |
907 |
807 |
+12.4 |
% | ||||||
|
Interest income |
5 |
6 |
-16.7 |
% | ||||||
|
Interest expense |
(71) |
(73) |
-2.7 |
% | ||||||
|
Income Before Income Taxes and Equity Interests |
841 |
740 |
+13.6 |
% | ||||||
|
Provision for income taxes |
(290) |
(224) |
+29.5 |
% | ||||||
|
Income Before Equity Interests |
551 |
516 |
+6.8 |
% | ||||||
|
Share of net income of equity companies |
31 |
49 |
-36.7 |
% | ||||||
|
Net Income |
582 |
565 |
+3.0 |
% | ||||||
|
Net income attributable to noncontrolling interests |
(20) |
(19) |
+5.3 |
% | ||||||
|
Net Income Attributable to |
$ |
562 |
$ |
546 |
+2.9 |
% | ||||
|
Per Share Basis |
||||||||||
|
Net Income Attributable to |
||||||||||
|
Basic |
$ |
1.51 |
$ |
1.43 |
+5.6 |
% | ||||
|
Diluted |
$ |
1.50 |
$ |
1.42 |
+5.6 |
% | ||||
|
Cash Dividends Declared |
$ |
0.84 |
$ |
0.81 |
+3.7 |
% | ||||
|
Common Shares Outstanding |
|
|||||||||
|
2014 |
2013 |
|||||||||
|
Outstanding shares as of |
372.5 |
382.1 |
||||||||
|
Average diluted shares for three months ended |
375.9 |
385.8 |
||||||||
|
N.M. - Not Meaningful |
|
Unaudited |
|
| ||||||||||
|
CONSOLIDATED INCOME STATEMENT | ||||||||||
|
(Millions, except per share amounts) | ||||||||||
|
Nine Months Ended |
||||||||||
|
2014 |
2013 |
Change | ||||||||
|
Net Sales |
$ |
16,063 |
$ |
15,847 |
+1.4 |
% | ||||
|
Cost of products sold |
10,528 |
10,420 |
+1.0 |
% | ||||||
|
Gross Profit |
5,535 |
5,427 |
+2.0 |
% | ||||||
|
Marketing, research and general expenses |
3,014 |
3,029 |
-0.5 |
% | ||||||
|
Other (income) and expense, net |
27 |
12 |
+125.0 |
% | ||||||
|
Operating Profit |
2,494 |
2,386 |
+4.5 |
% | ||||||
|
Interest income |
13 |
16 |
-18.8 |
% | ||||||
|
Interest expense |
(214) |
(211) |
+1.4 |
% | ||||||
|
Income Before Income Taxes and Equity Interests |
2,293 |
2,191 |
+4.7 |
% | ||||||
|
Provision for income taxes |
(749) |
(685) |
+9.3 |
% | ||||||
|
Income Before Equity Interests |
1,544 |
1,506 |
+2.5 |
% | ||||||
|
Share of net income of equity companies |
114 |
157 |
-27.4 |
% | ||||||
|
Net Income |
1,658 |
1,663 |
-0.3 |
% | ||||||
|
Net income attributable to noncontrolling interests |
(49) |
(60) |
-18.3 |
% | ||||||
|
Net Income Attributable to |
$ |
1,609 |
$ |
1,603 |
+0.4 |
% | ||||
|
Per Share Basis |
||||||||||
|
Net Income Attributable to |
||||||||||
|
Basic |
$ |
4.28 |
$ |
4.16 |
+2.9 |
% | ||||
|
Diluted |
$ |
4.25 |
$ |
4.13 |
+2.9 |
% | ||||
|
Cash Dividends Declared |
$ |
2.52 |
$ |
2.43 |
+3.7 |
% | ||||
|
Common Shares Outstanding |
|
|||||||||
|
2014 |
2013 |
|||||||||
|
Average diluted shares for nine months ended |
378.8 |
388.0 |
||||||||
|
Unaudited |
|
| ||||||||||||||||
|
NON-GAAP RECONCILIATIONS | ||||||||||||||||
|
(Millions, except per share amounts) | ||||||||||||||||
|
Three Months Ended | ||||||||||||||||
|
As Reported |
Charges for European Strategic Changes |
Charges Related to Health Care Spin-off |
As Adjusted Non-GAAP | |||||||||||||
|
Cost of products sold |
$ |
3,541 |
$ |
1 |
$ |
10 |
$ |
3,530 |
||||||||
|
Gross profit |
1,901 |
(1) |
(10) |
1,912 |
||||||||||||
|
Marketing, research and general expenses |
1,011 |
— |
30 |
981 |
||||||||||||
|
Operating profit |
907 |
(1) |
(40) |
948 |
||||||||||||
|
Income before income taxes and equity interests |
841 |
(1) |
(40) |
882 |
||||||||||||
|
Provision for income taxes |
(290) |
(2) |
(1) |
(287) |
||||||||||||
|
Effective tax rate |
34.5 |
% |
— |
— |
32.5 |
% | ||||||||||
|
Income before equity interests |
551 |
(3) |
(41) |
595 |
||||||||||||
|
Net income |
582 |
(3) |
(41) |
626 |
||||||||||||
|
Net income attributable to |
562 |
(3) |
(41) |
606 |
||||||||||||
|
Diluted earnings per share(a) |
1.50 |
(0.01) |
(0.11) |
1.61 |
||||||||||||
|
Three Months Ended | ||||||||||||
|
As Reported |
Charges for European Strategic Changes |
As Adjusted Non-GAAP | ||||||||||
|
Cost of products sold |
$ |
3,457 |
$ |
6 |
$ |
3,451 |
||||||
|
Gross profit |
1,805 |
(6) |
1,811 |
|||||||||
|
Marketing, research and general expenses |
990 |
5 |
985 |
|||||||||
|
Other (income) and expense, net |
8 |
3 |
5 |
|||||||||
|
Operating profit |
807 |
(14) |
821 |
|||||||||
|
Income before income taxes and equity interests |
740 |
(14) |
754 |
|||||||||
|
Provision for income taxes |
(224) |
4 |
(228) |
|||||||||
|
Effective tax rate |
30.3 |
% |
— |
30.2 |
% | |||||||
|
Income before equity interests |
516 |
(10) |
526 |
|||||||||
|
Net income |
565 |
(10) |
575 |
|||||||||
|
Net income attributable to |
546 |
(10) |
556 |
|||||||||
|
Diluted earnings per share(a) |
1.42 |
(0.03) |
1.44 |
|||||||||
|
(a) "As Adjusted Non-GAAP" does not equal "As Reported" plus "Charges" as a result of rounding. | |
|
Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. The company compensates for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures. | |
|
Unaudited | |
|
| ||||||||||||||||||||
|
NON-GAAP RECONCILIATIONS | ||||||||||||||||||||
|
(Millions, except per share amounts) | ||||||||||||||||||||
|
Nine Months Ended | ||||||||||||||||||||
|
As Reported |
Charges for European Strategic Changes |
Charges Related to Health Care Spin-off |
Charge Related to Regulatory Dispute in |
As Adjusted Non-GAAP | ||||||||||||||||
|
Cost of products sold |
$ |
10,528 |
$ |
9 |
$ |
59 |
$ |
— |
$ |
10,460 |
||||||||||
|
Gross profit |
5,535 |
(9) |
(59) |
— |
5,603 |
|||||||||||||||
|
Marketing, research and general expenses |
3,014 |
4 |
56 |
— |
2,954 |
|||||||||||||||
|
Other (income) and expense, net |
27 |
— |
— |
39 |
(12) |
|||||||||||||||
|
Operating profit |
2,494 |
(13) |
(115) |
(39) |
2,661 |
|||||||||||||||
|
Income before income taxes and equity interests |
2,293 |
(13) |
(115) |
(39) |
2,460 |
|||||||||||||||
|
Provision for income taxes |
(749) |
1 |
21 |
— |
(771) |
|||||||||||||||
|
Effective tax rate |
32.7 |
% |
— |
— |
— |
31.3 |
% | |||||||||||||
|
Income before equity interests |
1,544 |
(12) |
(94) |
(39) |
1,689 |
|||||||||||||||
|
Net income |
1,658 |
(12) |
(94) |
(39) |
1,803 |
|||||||||||||||
|
Net income attributable to noncontrolling interests |
(49) |
— |
— |
20 |
(69) |
|||||||||||||||
|
Net income attributable to |
1,609 |
(12) |
(94) |
(19) |
1,734 |
|||||||||||||||
|
Diluted earnings per share |
4.25 |
(0.03) |
(0.25) |
(0.05) |
4.58 |
|||||||||||||||
|
Nine Months Ended | ||||||||||||||||
|
As Reported |
Charges for European Strategic Changes |
Charge for Venezuelan Bolivar Devaluation |
As Adjusted Non-GAAP | |||||||||||||
|
Cost of products sold |
$ |
10,420 |
$ |
44 |
$ |
— |
$ |
10,376 |
||||||||
|
Gross profit |
5,427 |
(44) |
— |
5,471 |
||||||||||||
|
Marketing, research and general expenses |
3,029 |
20 |
— |
3,009 |
||||||||||||
|
Other (income) and expense, net |
12 |
3 |
36 |
(27) |
||||||||||||
|
Operating profit |
2,386 |
(67) |
(36) |
2,489 |
||||||||||||
|
Income before income taxes and equity interests |
2,191 |
(67) |
(36) |
2,294 |
||||||||||||
|
Provision for income taxes |
(685) |
15 |
10 |
(710) |
||||||||||||
|
Effective tax rate |
31.3 |
% |
— |
— |
31.0 |
% | ||||||||||
|
Income before equity interests |
1,506 |
(52) |
(26) |
1,584 |
||||||||||||
|
Net income |
1,663 |
(52) |
(26) |
1,741 |
||||||||||||
|
Net income attributable to |
1,603 |
(52) |
(26) |
1,681 |
||||||||||||
|
Diluted earnings per share |
4.13 |
(0.13) |
(0.07) |
4.33 |
||||||||||||
|
Unaudited |
|
| |||||||
|
CONSOLIDATED BALANCE SHEET | |||||||
|
(Millions) | |||||||
|
|
| ||||||
|
ASSETS |
|||||||
|
Current Assets |
|||||||
|
Cash and cash equivalents |
$ |
1,431 |
$ |
1,054 |
|||
|
Accounts receivable, net |
2,542 |
2,545 |
|||||
|
Inventories |
2,281 |
2,233 |
|||||
|
Other current assets |
667 |
718 |
|||||
|
Total Current Assets |
6,921 |
6,550 |
|||||
|
Property, Plant and Equipment, Net |
7,692 |
7,948 |
|||||
|
Investments in Equity Companies |
335 |
382 |
|||||
|
Goodwill |
3,129 |
3,181 |
|||||
|
Other Intangible Assets |
215 |
243 |
|||||
|
Other Assets |
584 |
615 |
|||||
|
TOTAL ASSETS |
$ |
18,876 |
$ |
18,919 |
|||
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||||
|
Current Liabilities |
|||||||
|
Debt payable within one year |
$ |
773 |
$ |
375 |
|||
|
Redeemable preferred securities of subsidiary |
506 |
506 |
|||||
|
Trade accounts payable |
2,597 |
2,598 |
|||||
|
Accrued expenses |
2,071 |
2,060 |
|||||
|
Dividends payable |
313 |
309 |
|||||
|
Total Current Liabilities |
6,260 |
5,848 |
|||||
|
Long-Term Debt |
5,633 |
5,386 |
|||||
|
Noncurrent Employee Benefits |
1,090 |
1,312 |
|||||
|
Deferred Income Taxes |
902 |
817 |
|||||
|
Other Liabilities |
371 |
344 |
|||||
|
|
72 |
72 |
|||||
|
Stockholders' Equity |
|||||||
|
|
4,265 |
4,856 |
|||||
|
Noncontrolling Interests |
283 |
284 |
|||||
|
Total Stockholders' Equity |
4,548 |
5,140 |
|||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
18,876 |
$ |
18,919 |
|||
|
2014 Data is Unaudited |
|
| |||||||||||||||
|
CONSOLIDATED CASH FLOW STATEMENT | |||||||||||||||
|
(Millions) | |||||||||||||||
|
Three Months Ended |
Nine Months Ended | ||||||||||||||
|
2014 |
2013 |
2014 |
2013 | ||||||||||||
|
Operating Activities |
|||||||||||||||
|
Net income |
$ |
582 |
$ |
565 |
$ |
1,658 |
$ |
1,663 |
|||||||
|
Depreciation and amortization |
220 |
208 |
655 |
641 |
|||||||||||
|
Asset impairments |
— |
42 |
42 |
42 |
|||||||||||
|
Stock-based compensation |
15 |
21 |
51 |
73 |
|||||||||||
|
Deferred income taxes |
(6) |
58 |
57 |
128 |
|||||||||||
|
Net (gains) losses on asset dispositions |
(6) |
(5) |
(11) |
— |
|||||||||||
|
Equity companies' earnings in excess of dividends paid |
9 |
(9) |
(27) |
(75) |
|||||||||||
|
(Increase) decrease in operating working capital |
152 |
29 |
(63) |
(259) |
|||||||||||
|
Postretirement benefits |
16 |
13 |
(119) |
(135) |
|||||||||||
|
Other |
(6) |
(10) |
12 |
17 |
|||||||||||
|
Cash Provided by Operations |
976 |
912 |
2,255 |
2,095 |
|||||||||||
|
Investing Activities |
|||||||||||||||
|
Capital spending |
(291) |
(203) |
(730) |
(697) |
|||||||||||
|
Acquisitions of businesses |
— |
(30) |
— |
(32) |
|||||||||||
|
Proceeds from dispositions of property |
27 |
27 |
36 |
113 |
|||||||||||
|
Proceeds from sales of investments |
3 |
6 |
96 |
16 |
|||||||||||
|
Investments in time deposits |
(10) |
(46) |
(123) |
(46) |
|||||||||||
|
Maturities of time deposits |
9 |
46 |
191 |
66 |
|||||||||||
|
Other |
18 |
1 |
5 |
(10) |
|||||||||||
|
Cash Used for Investing |
(244) |
(199) |
(525) |
(590) |
|||||||||||
|
Financing Activities |
|||||||||||||||
|
Cash dividends paid |
(315) |
(311) |
(942) |
(913) |
|||||||||||
|
Change in short-term borrowings |
(126) |
289 |
153 |
22 |
|||||||||||
|
Debt proceeds |
5 |
3 |
621 |
889 |
|||||||||||
|
Debt repayments |
(3) |
(502) |
(109) |
(542) |
|||||||||||
|
Cash paid on redeemable preferred securities of subsidiaries |
(8) |
(7) |
(22) |
(21) |
|||||||||||
|
Proceeds from exercise of stock options |
17 |
18 |
98 |
164 |
|||||||||||
|
Acquisitions of common stock for the treasury |
(205) |
(165) |
(1,122) |
(959) |
|||||||||||
|
Other |
(7) |
(1) |
— |
7 |
|||||||||||
|
Cash Used for Financing |
(642) |
(676) |
(1,323) |
(1,353) |
|||||||||||
|
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
(28) |
(18) |
(30) |
(79) |
|||||||||||
|
Increase (Decrease) in Cash and Cash Equivalents |
62 |
19 |
377 |
73 |
|||||||||||
|
Cash and Cash Equivalents - Beginning of Period |
1,369 |
1,160 |
1,054 |
1,106 |
|||||||||||
|
Cash and Cash Equivalents - End of Period |
$ |
1,431 |
$ |
1,179 |
$ |
1,431 |
$ |
1,179 |
|||||||
|
Unaudited |
|
| ||||||||||||||||||||||
|
SELECTED BUSINESS SEGMENT DATA | ||||||||||||||||||||||
|
(Millions) | ||||||||||||||||||||||
|
Three Months Ended |
Nine Months Ended |
|||||||||||||||||||||
|
2014 |
2013 |
Change |
2014 |
2013 |
Change | |||||||||||||||||
|
NET SALES |
||||||||||||||||||||||
|
Personal Care |
$ |
2,475 |
$ |
2,383 |
+3.9 |
% |
$ |
7,299 |
$ |
7,170 |
+1.8 |
% | ||||||||||
|
Consumer Tissue |
1,697 |
1,626 |
+4.4 |
% |
5,024 |
4,969 |
+1.1 |
% | ||||||||||||||
|
K-C Professional |
873 |
843 |
+3.6 |
% |
2,531 |
2,477 |
+2.2 |
% | ||||||||||||||
|
Health Care |
392 |
403 |
-2.7 |
% |
1,186 |
1,201 |
-1.2 |
% | ||||||||||||||
|
Corporate & Other |
5 |
7 |
N.M. |
23 |
30 |
N.M. | ||||||||||||||||
|
TOTAL NET SALES |
$ |
5,442 |
$ |
5,262 |
+3.4 |
% |
$ |
16,063 |
$ |
15,847 |
+1.4 |
% | ||||||||||
|
OPERATING PROFIT |
||||||||||||||||||||||
|
Personal Care |
$ |
483 |
$ |
427 |
+13.1 |
% |
$ |
1,393 |
$ |
1,300 |
+7.2 |
% | ||||||||||
|
Consumer Tissue |
285 |
233 |
+22.3 |
% |
782 |
713 |
+9.7 |
% | ||||||||||||||
|
K-C Professional |
165 |
155 |
+6.5 |
% |
455 |
459 |
-0.9 |
% | ||||||||||||||
|
Health Care |
52 |
70 |
-25.7 |
% |
187 |
168 |
+11.3 |
% | ||||||||||||||
|
Corporate & Other(a) |
(95) |
(70) |
N.M. |
(296) |
(242) |
N.M. | ||||||||||||||||
|
Other (income) and expense, net |
(17) |
8 |
N.M. |
27 |
12 |
+125.0 |
% | |||||||||||||||
|
TOTAL OPERATING PROFIT |
$ |
907 |
$ |
807 |
+12.4 |
% |
$ |
2,494 |
$ |
2,386 |
+4.5 |
% | ||||||||||
|
(a) |
Corporate & Other includes charges related to the European strategic changes of |
|
N.M. - Not Meaningful | |
|
Unaudited |
|
| ||||||||||||||||||
|
SELECTED BUSINESS SEGMENT DATA | ||||||||||||||||||
|
PERCENTAGE CHANGE IN NET SALES VERSUS PRIOR YEAR | ||||||||||||||||||
|
Three Months Ended | ||||||||||||||||||
|
Total |
Organic Volume |
Restructuring Impact(a) |
Net Price |
Mix/ Other(b) |
Currency | |||||||||||||
|
Consolidated |
3.4 |
2 |
— |
2 |
(1) |
— |
||||||||||||
|
Personal Care |
3.9 |
2 |
— |
3 |
— |
(1) |
||||||||||||
|
Consumer Tissue |
4.4 |
3 |
— |
1 |
(1) |
1 |
||||||||||||
|
K-C Professional |
3.6 |
3 |
— |
— |
— |
1 |
||||||||||||
|
Health Care |
(2.7) |
— |
— |
(3) |
— |
— |
||||||||||||
|
Nine Months Ended | ||||||||||||||||||
|
Total |
Organic Volume |
Restructuring Impact(a) |
Net Price |
Mix/ Other(b) |
Currency | |||||||||||||
|
Consolidated |
1.4 |
3 |
(1) |
2 |
(1) |
(2) |
||||||||||||
|
Personal Care |
1.8 |
4 |
(1) |
2 |
— |
(3) |
||||||||||||
|
Consumer Tissue |
1.1 |
1 |
(2) |
2 |
— |
— |
||||||||||||
|
K-C Professional |
2.2 |
2 |
— |
1 |
— |
(1) |
||||||||||||
|
Health Care |
(1.2) |
1 |
— |
(2) |
— |
— |
||||||||||||
|
(a) |
Lower sales related to the European strategic changes and the 2011 and 2012 pulp and tissue restructuring actions. |
|
(b) |
Mix/Other includes rounding. |
|
Unaudited |
|
| ||||||||||||||||
|
ADDITIONAL NON-GAAP RECONCILIATIONS | ||||||||||||||||
|
(Millions, except per share amounts) | ||||||||||||||||
|
NINE MONTHS ENDED |
2014 |
2013 | ||||||||||||||
|
Net Income Attributable to KCC |
Diluted Earnings Per Share |
Net Income Attributable to KCC |
Diluted Earnings Per Share | |||||||||||||
|
As adjusted earnings Non-GAAP |
$ |
1,734 |
$ |
4.58 |
$ |
1,681 |
$ |
4.33 |
||||||||
|
Separation of health care business(a) |
(159) |
(0.42) |
(150) |
(0.39) |
||||||||||||
|
Rounding |
— |
— |
— |
0.01 |
||||||||||||
|
As adjusted earnings from continuing operations(b) |
$ |
1,575 |
$ |
4.16 |
$ |
1,531 |
$ |
3.95 |
||||||||
|
FULL YEAR 2013 EARNINGS |
Income |
Diluted Earnings Per Share | ||||||
|
Previously reported adjusted earnings |
$ |
2,234 |
$ |
5.77 |
||||
|
Separation of health care business(a) |
(203) |
(0.52) |
||||||
|
Rounding |
— |
(0.01) |
||||||
|
Adjusted earnings from continuing operations(b) |
2,031 |
5.24 |
||||||
|
Previously reported adjusted earnings |
$ |
2,234 |
$ |
5.77 |
||||
|
Adjustments for: |
||||||||
|
Charges for European strategic changes |
(66) |
(0.17) |
||||||
|
Charge for devaluation of Venezuelan bolivar |
(26) |
(0.07) |
||||||
|
Net income attributable to |
$ |
2,142 |
$ |
5.53 |
||||
|
(a) |
Represents health care operating results, excluding overhead costs previously allocated to health care that will remain part of |
|
|
(b) |
Expected to be equivalent to adjusted earnings from continuing operations after the spin-off of the health care business. |
|
|
Unaudited |
|
| ||||||||||
|
ADDITIONAL NON-GAAP RECONCILIATIONS (OUTLOOK) | ||||||||||
|
| ||||||||||
|
ESTIMATED FULL YEAR 2014 DILUTED EARNINGS PER SHARE |
||||||||||
|
Adjusted earnings per share(a) |
$ |
5.93 |
- |
$ |
6.03 |
|||||
|
Separation of health care business(b) |
(0.47) |
- |
(0.47) |
|||||||
|
Adjusted earnings per share from continuing operations(c) |
$ |
5.46 |
- |
$ |
5.56 |
|||||
|
Adjusted earnings per share(a) |
$ |
5.93 |
- |
$ |
6.03 |
|||||
|
Adjustments for: |
||||||||||
|
Charges related to spin-off of health care business(d) |
(0.25) |
- |
(0.25) |
|||||||
|
Charge related to regulatory dispute in |
(0.05) |
- |
(0.05) |
|||||||
|
Charges for European strategic changes |
(0.07) |
- |
(0.06) |
|||||||
|
Charges related to 2014 organization restructuring |
(0.28) |
- |
(0.23) |
|||||||
|
Per share basis - diluted net income attributable to |
$ |
5.28 |
- |
$ |
5.44 |
|||||
|
ESTIMATED FULL YEAR 2014 EFFECTIVE TAX RATE |
||||||||||
|
Adjusted effective tax rate |
31.0 |
% |
- |
32.5 |
% | |||||
|
Adjustments for: |
||||||||||
|
Charges related to spin-off of health care business(d) |
0.5 |
- |
0.5 |
|||||||
|
Charge related to regulatory dispute in |
0.4 |
- |
0.4 |
|||||||
|
Charges for European strategic changes |
0.1 |
- |
0.2 |
|||||||
|
Charges related to 2014 organization restructuring |
— |
0.1 |
||||||||
|
Effective tax rate |
32.0 |
% |
- |
33.7 |
% | |||||
|
(a) |
Includes 10 months of operating results of the health care business prior to the spin-off effective |
|
(b) |
Represents 10 months of health care operating results, excluding overhead costs previously allocated to health care that will remain part of |
|
(c) |
Expected to be equivalent to adjusted earnings from continuing operations after the spin-off of the health care business. |
|
(d) |
Represents charges through |
Logo - http://photos.prnewswire.com/prnh/20110928/DA76879LOGO
[KMB-F]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kimberly-clark-announces-third-quarter-2014-results-287248465.html
SOURCE
News Provided by Acquire Media